A novel programme to evaluate and communicate 10-year risk of CHD reduces predicted risk and improves patients’ modifiable risk factor profile

J. S. Benner,1 L. Erhardt,2 M. Flammer,3 R. A. Moller,3 N. Rajicic,3 K. Changela,3 C. Yunis,3 S. B. Cherry,1 Z. Gaciong,4 E. S. Johnson,5 M. C. J. M. Sturkenboom,6 J. Garcia-Puig,7 X. Girerd8, on behalf of the REACH OUT Investigators*

SUMMARY

Aims: We assessed whether a novel programme to evaluate/communicate predicted coronary heart disease (CHD) risk could lower patients’ predicted Framingham CHD risk vs. usual care. Methods: The Risk Evaluation and Communication Health Outcomes and Utilization Trial was a prospective, controlled, cluster-randomised trial in nine European countries, among patients at moderate cardiovascular risk. Following baseline assessments, physicians in the intervention group calculated patients’ predicted CHD risk and were instructed to advise patients according to a risk evaluation/communication programme. Usual care physicians did not calculate patients’ risk and provided usual care only. The primary end-point was Framingham 10-year CHD risk at 6 months with intervention vs. usual care. Results: Of 1103 patients across 100 sites, 524 patients receiving intervention, and 461 receiving usual care, were analysed for efficacy. After 6 months, mean predicted risks were 12.5% with intervention, and 13.7% with usual care [odds ratio = 0.896; p = 0.001, adjusted for risk at baseline (17.2% intervention; 16.9% usual care) and other covariates]. The proportion of patients achieving both blood pressure and low-density lipoprotein cholesterol targets was significantly higher with intervention (25.4%) than usual care (14.1%; p < 0.001), and 29.3% of smokers in the intervention group quit smoking vs. 21.4% of those receiving usual care (p = 0.04). Conclusions: A physician-implemented CHD risk evaluation/communication programme improved patients’ modifiable risk factor profile, and lowered predicted CHD risk compared with usual care. By combining this strategy with more intensive treatment to reduce residual modifiable risk, we believe that substantial improvements in cardiovascular disease prevention could be achieved in clinical practice.

Introduction

Coronary heart disease (CHD) is the most prevalent form of cardiovascular disease (CVD) and the most common cause of death worldwide (1). Hypertension, dyslipidaemia and cigarette smoking are the three modifiable risk factors most strongly and independently associated with CHD (2,3). Pharmacologic and lifestyle interventions targeting these risk factors have been shown in large clinical trials and meta-analyses to reduce the risk of CHD death (4–8). However, despite the proven benefits of such interventions, improvements in modifiable risk factors remain suboptimal in clinical practice (9–14). Potential reasons for this treatment gap are lack of physician implementation of guidelines and poor patient adherence to recommended drug therapies or lifestyle modifications (14–18). In particular, despite advances in therapies in recent years, improvements in lifestyle factors among patients at risk for CVD have been minimal (14). Novel strategies for CVD prevention are urgently required to help motivate patients and physicians towards improving the reductions in modifiable risk factors achieved in clinical practice, and thus lower patients’ overall risk of CHD.

Evidence-based guidelines, such as those from the Fourth Joint Task Force of European and Other
Societies on Cardiovascular Disease Prevention in Clinical Practice (19) and the National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III (20), have emphasised the importance of considering overall cardiovascular risk in CVD management. Frequently, usual care in clinical practice involves the treatment of individual risk factors to target levels, however, a more global approach is needed to effectively lower patients’ overall risk (18). Global risk equations, including the Framingham (21), Prospective Cardiovascular Munster (22) and Systematic COronary Risk Evaluation (23) models, can estimate overall CVD/CHD risk based on a patient’s age, sex, blood pressure, cholesterol, smoking status and other cardiovascular risk factors. While some previous studies have investigated the benefits of assessing and communicating patients’ predicted CVD/CHD risk for improving risk factor management, these interventions have had limited benefits (24–26).

Recently, the large EuroAction trial evaluated the efficacy of a nurse-led, multidimensional approach that aimed to educate and support coronary patients and those at risk for CVD to comply with guideline-recommended treatments and lifestyle changes. Compared with patients receiving usual care, patients receiving this intervention showed significant improvements in cardiovascular risk factors and compliance with lifestyle changes (27–29). Several other studies evaluating strategies designed to educate or motivate physicians and patients have reported positive changes in patient behaviour and efficacy outcomes as a result of similar interventions (30–37).

We developed a novel CHD risk evaluation and communication programme that aimed to incorporate the concept of global predicted risk into a comprehensive intervention strategy designed both to facilitate clinical decision making by physicians and to educate and motivate patients to reduce their global cardiovascular risk. This intervention programme utilises the Framingham risk calculation for the assessment of 10-year CHD risk. Although the Framingham model is not intended to assess treatment effects, we believe that this can provide a useful tool to communicate a patient’s global risk, and that relative changes in predicted Framingham 10-year risk following intervention can provide an indication of the potential achievable benefits if improvements are maintained over the long term. The Risk Evaluation And Communication Health Outcomes and Utilization Trial (REACH OUT) was therefore conducted to evaluate the clinical utility of our CHD risk evaluation/communication programme for lowering CHD risk as measured by Framingham risk equations, in comparison with usual care, in a multi-country setting (38).

Methods

Study design

The REACH OUT study was a 6-month, parallel group, prospective, controlled, cluster-randomised, multinational trial conducted between September 2005 and November 2006. The study design has been described in more detail in a previous publication (38). Briefly, study sites in nine European countries (Czech Republic, Denmark, France, Germany, Greece, The Netherlands, Poland, Spain and Sweden) were randomised in a 1:1 ratio to deliver either usual care following screening or a CHD risk evaluation and communication programme.

A cluster-randomised design was selected in order that physicians were not required to administer both usual care and the intervention, as physician education during the intervention programme may have influenced their approach to usual care. Cluster randomisation was performed by randomly selecting pairs of study sites within each block of 10 sites using a computer-based algorithm, and randomly assigning them to the intervention or usual care arm. At each site physicians screened patients from an alphabetical list of potential study participants, taken from the physicians’ files, to identify 100 patients who met initial criteria. Using a random permutation of 100 numbers, patients were then sequentially screened and consented until 10–15 patients had been enrolled per site. All study sites were required to adhere to Good Clinical Practice/International Conference on Harmonization guidelines, and the study protocol was reviewed and approved by the relevant ethics committee in each participating country.

Inclusion/exclusion criteria

Patients had to be 45–64 years of age with a history of hypertension, systolic blood pressure ≥ 140 mmHg (or ≥ 130 mmHg for patients with renal disease) (39,40), and a 10-year risk of myocardial infarction (MI) or death because of CHD of ≥ 10% as predicted by the Framingham equation (41). Exclusion criteria included a history of CHD or diabetes mellitus, or a fasting plasma glucose > 6.9 mmol/l (124 mg/dl) at screening. Physicians were required to be certified General Practitioners or Internists who were not using CHD risk algorithms in their routine practice prior to the study.

Programmes

In both the usual care and intervention groups, screening was conducted by recording patients’ characteristics and risk factors using a small, portable, touch-screen computer [Touch Outcomes Collector (TOC); ASSIST Technologies, Scottsdale, AZ]. The and C. Yunis are employees of Pfizer Inc. Z. Gasior has received research contracts and acted as speaker and consultant for Pfizer Inc. J. Garcia-Puig has acted as speaker and consultant for Pfizer Inc, Novartis, AstraZeneca and Boehringer Ingelheim. E. S. Johnson has received honoraria and acted as consultant for Pfizer Inc. X. Girend has acted as consultant for Pfizer Inc. M. C. J. M. Sturkenboom has received research grants from Pfizer Inc, Merck, Amgen and Johnson & Johnson and has served on advisory boards for Pfizer Inc., Servier, Lundbeck, Novartis and Celgene.

*REACH OUT, the Risk Evaluation And Communication Health Outcomes and Utilization Trial.

Re-use of this article is permitted in accordance with the Creative Commons Deed, Attribution 2.5, which does not permit commercial exploitation.
TOC analysed the patient’s risk factor profile and calculated the Framingham risk, which was the basis for inclusion in the study.

In the usual care group, physicians were provided with the study protocol, which included an explanation of the purpose of the trial, and received training on the use of the TOC. Predicted Framingham 10-year risk of CHD was calculated but was not communicated to either the physician or patient until the final visit, when the patient’s risk at baseline and at month 6 was reviewed with the patient by the physician (although for ethical reasons, laboratory results used to assess risk were available to the physician during the study period), and physicians were instructed locally to provide usual care only during the study period (Figure 1).

In the intervention group, physicians received training in risk assessment and communication as part of an investigator meeting prior to enrolling patients (usual care physicians were not invited to participate). At weeks 1–2, physicians were informed of patients’ predicted CHD risk and were instructed to advise the patient according to a CHD risk evaluation and communication programme (Figure 1). This was designed to inform patients of their predicted absolute and potentially modifiable 10-year risk of CHD (excluding the impact of age and sex on predicted risk), and to educate them about modifiable risk factors and their control through behavioural changes and drug therapy. As part of the intervention, patients received a Heart Health Report (38) (Figure S1) generated by the TOC and based on the patient’s risk factor profile, which was reviewed with the physician at the same visit (Figure 1). The report illustrated modifiable risk with a bar chart comparing the patient’s predicted absolute risk with that of a non-smoker of the same age and sex with ‘normal’ untreated blood pressure (defined in this study as systolic blood pressure = 139 mmHg) and cholesterol levels [total cholesterol = 4.9 mmol/l (189 mg/dl); high-density lipoprotein cholesterol (HDL-C) = 1.0 mmol/l (40 mg/dl) for males or 1.2 mmol/l (46 mg/dl) for females] (38).

The intervention also involved three follow-up phone calls by a physician or study nurse at weeks 6, 12 and 18, and patients completed a ‘Knowledge, Attitudes and Behaviour’ (KAB) questionnaire at week 0 and week 22–23 (designed specifically for the purposes of this trial) (Figure 1). Responses to 3–5 multiple-choice questions within each domain of the KAB questionnaire were summed, with possible scores in the range of 0–5 for knowledge, 5–25 for attitudes and 3–15 for behaviour; higher scores indicating more positive responses. A fourth domain was included with multiple-choice questions designed to assess patient satisfaction with the intervention and physician compliance with the protocol. The Heart Health Report and KAB questionnaire have been described in more detail previously (38).

In both the usual care and intervention groups, all medications (including cardiovascular medications) were prescribed at the discretion of the physician.

**Efficacy measures**

**Primary efficacy measure**

The primary efficacy measure was the Framingham 10-year predicted risk of MI or CHD death at month 6 in the intervention group vs. the usual care group. Calculation of 10-year predicted risk of CHD was based on the Framingham model employed in the NCEP ATP III risk assessment tool (41); variables

![Figure 1](attachment:study_flow_diagram.png)
predicted risk of CHD at month 6 was evaluated using statistical simulation methods. Programs: sampsi and sampclus, and confirmed the calculation. This sample size was estimated using the calculation: \[
\frac{(r_1 - r_2) / r_2} {100\%},
\]
where \(r_1\) is the risk for the patient, and \(r_2\) is the risk for the normal individual. Therefore, a patient with twice the predicted risk of a normal individual would have a modifiable risk of 100%. As the parameters used to define \(r_2\) were values below which risk could be further reduced with intensive treatment (42–50), our definition of \(r_2\) and thus our definition of modifiable risk were conservative.

Additional secondary measures included changes in blood pressure and lipids, attainment of blood pressure (< 140/90 mmHg) and low-density lipoprotein cholesterol [LDL-C; < 3.4 mmol/l (130 mg/dl)] goals (20,39,40), weight loss, and changes in smoking status. Adverse events (AEs) were also monitored.

### Statistical analyses

The study was designed to enrol a total of 110 sites each with 11 evaluable patients, to provide at least 80% power to detect a 10% relative difference in the primary end-point of Framingham 10-year risk at month 6 at a 5% significance level. Standard deviation of the primary end-point was assumed to be 0.35 (on the natural logarithm scale).

Given the cluster-randomised design, the intra-class correlation (ICC) of patients from the same site was considered, where an ICC of 0.05 was used in the calculation. This sample size was estimated using two Stata (version 8.2; College Station, TX, USA) programs: sampsi and sampclus, and confirmed using statistical simulation methods.

The primary end-point of the Framingham 10-year predicted risk of CHD at month 6 was evaluated using a mixed effects model (SAS® MIXED procedure; SAS Institute, Cary, NC, USA). As the distribution of the Framingham risk score is often highly skewed, the natural logarithm of the primary efficacy end-point was used as the response variable, with the study group, country, gender, age and a logarithm of the 10-year predicted Framingham risk at baseline as covariate terms in the model.

The primary analysis was the calculation of a two-sided p-value, and the 95% confidence interval, for the difference between least squares mean values for the intervention and usual care groups at month 6.

### Results

#### Patient population

Overall, 101 study sites were randomised to deliver usual care or the risk evaluation and communication programme. Of these, one site in the intervention arm was excluded because of not returning the appropriate local approval documentation. From the 100 sites included in the analysis (50 in each group), 1103 patients were recruited; 1076 completed the study and 985 were eligible for inclusion in the primary efficacy analysis (461 allocated to usual care; 524 patients allocated to intervention) (Figure 2). Of the 118 patients excluded from the efficacy analysis, for 91 patients this was due to failure of the TOC to capture the data correctly; 26 patients discontinued from the study and one patient was ongoing at cut-off (Figure 2). The estimated sample size of 1210 patients was not met; however, as the observed dropout rate was lower than predicted, the study remained adequately powered.

Among the overall study population, mean age was 57 years and approximately 14% of patients were female. On average, patients were overweight (mean body mass index was 29 kg/m²), and over half were smokers. While 18% had a history of dyslipidaemia according to patients’ medical records, 51% were retrospectively classified with dyslipidaemia based on their lipids and medications at screening. Only 3% had a prior history of non-CHD cardiac disorders (Table 1).

For patients included in the efficacy analysis, at the beginning of the study, 82.4% of usual care patients were receiving cardiovascular medications; 80.9% were receiving antihypertensives and 23.9% were on serum lipid-reducing medications. Among intervention patients, 81.5%, 77.9% and 27.1% were taking cardiovascular medications, antihypertensives and serum lipid-reducing agents, respectively (Table 3). More than half of patients in both groups were receiving agents acting on the renin–angiotensin system at screening.

#### Predicted 10-year risk of non-fatal MI or CHD death

After 6 months, the mean (SE) predicted 10-year risk of non-fatal MI or fatal CHD was reduced from baseline [16.9% (0.26) in the usual care group; 17.2% (0.25) in the intervention group], to 13.7% (0.27) and 12.5% (0.25) among usual care
and intervention patients respectively (Table 2). This corresponds to a relative decrease in predicted risk of 18.2% in the usual care group, compared with 25.7% among patients receiving the intervention.

Following adjustments for baseline risk and other covariates (including country, age, gender and baseline risk), predicted absolute 10-year risk of CHD at month 6 in the intervention group was 0.896 times that in the usual care group (95% CI: 0.84–0.96; p = 0.001) (Table 2). The mean change in predicted absolute risk for the intervention vs. usual care was −6.3 in the intervention group and −4.9 in the usual care group, corresponding to a between-group difference of −1.4 (95% CI: −2.1 to −0.8; p < 0.001; ICC = 0.033).

Figure 2 Patient flow. AEs, adverse events; TOC, Touch Outcomes Collector
The changes in modifiable risk of CHD (i.e. the risk attributable to cardiovascular risk factors that can be altered by lifestyle changes and/or medication) in the usual care and intervention groups are given in Table 2. At baseline, patients in the usual care and intervention groups had a modifiable CHD risk of 221% and 192%, respectively (i.e. on average their predicted risk was approximately three times that of a non-smoker of the same age and sex with normal untreated blood pressure and...
lipids). After 6 months, the modifiable risk was substantially lowered in both groups but was still 117% in the usual care group, vs. 87% in the intervention group. After adjusting for baseline risk and other covariates, the mean absolute difference in the change in modifiable risk with the intervention vs. usual care was −18.5% (95% CI: −35.5 to −1.4; p = 0.034) (Table 2).

**Changes in modifiable risk factors and weight loss**

Over the 6 month study period, mean blood pressure was reduced from 159/94 to 144/87 mmHg in the usual care group, and from 157/93 to 138/85 mmHg in the intervention group. After adjusting for baseline values and other covariates, blood pressure was reduced significantly more among patients receiving the intervention than among those receiving usual care (p < 0.01) (Figure 3A).

Baseline LDL-C was approximately 3.9 mmol/l (~150 mg/dl) in both groups, which was reduced to 3.5 mmol/l (135 mg/dl) and 3.4 mmol/l (131 mg/dl) in the usual care and intervention groups respectively, after 6 months. After adjustments, a slightly greater decrease in LDL-C was observed in the intervention group than with usual care, although the difference between groups was not significant (p = 0.052) (Figure 3B). Similarly, total cholesterol was reduced from approximately 5.9 mmol/l (228 mg/dl) in both groups to 5.6 mmol/l (216 mg/dl) in the usual care group compared with 5.4 mmol/l (211 mg/dl) in the intervention group; the between-group difference for these reductions was not significant (p = 0.095).

**Figure 3** Changes in modifiable risk factors. (A) Change in blood pressure. (B) Change in lipids. (C) Attainment of blood pressure and LDL-C goals. (D) Change in smoking status. **p < 0.0001 vs. baseline. †At baseline, 28.9% and 29.8% of patients in the usual care and intervention groups respectively, were at LDL-C goal; < 1% of patients were at blood pressure goal at baseline. BP, blood pressure; LS, least square; CI, confidence interval; TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol.
From baseline to month 6, there was a non-significant increase in triglycerides of 3.7\% (95\% CI: -2.8 to 10.3; \( p = 0.26 \)) in the usual care group, and 3.2\% (95\% CI: -3.1 to 9.4; \( p = 0.32 \)) in the intervention group (\( p = 0.88 \) between groups).

Overall, a significantly higher proportion of patients in the intervention group achieved blood pressure and LDL-C goals than in the usual care group (Figure 3C). Patients in the intervention group were 1.9 times (95\% CI: 1.2 to 2.9; \( p = 0.003 \)) as likely to attain their blood pressure goal; 1.6 times (95\% CI: 1.2 to 2.2; \( p = 0.005 \)) as likely to attain LDL-C goal and 2.1 times (95\% CI: 1.3 to 3.3; \( p = 0.002 \)) as likely to attain both goals as patients in the usual care group.

Within the intervention group, 97\% of smokers were encouraged to stop smoking by the physician (6.3\% of all patients were prescribed anti-smoking medications). Among these patients, 29.3\% were reported to have quit smoking at the end of the study, compared with 21.4\% of smokers in the usual care group (\( p = 0.04 \)) (Figure 3D).

Across both treatment groups, reductions in predicted modifiable risk (Table 2) were driven predominantly by decreases in systolic blood pressure (accounting for 25.5\% of the risk reduction), followed by changes in total cholesterol (21.6\% of the risk reduction), and quitting smoking (15.7\% of the risk reduction), while only 7.8\% of the modifiable risk reduction was due to increases in HDL-C (percentages are based on analysis of variance components from a regression model; the difference from the sum of percentages to 100\% is the remainder of the variability unexplained by the model).

Within the intervention group, after adjusting for covariates at baseline, patients achieved a mean decrease in weight of 1.14 kg (95\% CI: 1.71 to 0.56), which although marginal, was statistically significantly greater than the mean change in weight among usual care patients [\( -0.35 \) kg (95\% CI: -0.95 to 0.25); \( p = 0.015 \)].

**Patient responses to KAB questionnaire**

At month 6, among patients in the intervention group, mean scores increased by 7\%, 5\% and 12\%, from baseline values of 4.4, 21.8 and 11.6 (\( p < 0.0001 \) from baseline for all) for the knowledge, attitudes, and behaviour domains of the questionnaire, respectively. Increased scores for attitudes correlated significantly (\( p = 0.014 \)) with reductions in modifiable Framingham risk, while knowledge and behaviour scores showed no significant correlation with modifiable risk reduction. In addition, scores for attitudes and behaviour, but not knowledge, correlated significantly (\( p < 0.0001 \) and \( p = 0.0048 \)) with decreases in blood pressure. None of the scores correlated with lipid changes. Over three-quarters of patients (77.5\%) reported that their physician spent >5 min explaining the Heart Health Report. When asked their favourite part of the intervention in

| Patients receiving medications, n (%) | Usual care (\( N = 461 \)) | Intervention (\( N = 524 \)) |
|---------------------------------------|-----------------------------|-----------------------------|
|                                       | Screening | Final visit | % Change | Screening | Final visit | % Change |
| Any cardiovascular medications        | 82.4      | 93.3       | 13.2      | 81.5      | 89.1       | 9.4       |
| Any antihypertensive                  | 80.9      | 91.1       | 12.6      | 77.9      | 84.7       | 8.8       |
| ACE inhibitors                        | 29.3      | 33.0       | 12.6      | 22.0      | 27.3       | 24.3      |
| ACE inhibitor combinations            | 5.0       | 6.5        | 30.4      | 4.8       | 5.9        | 24.0      |
| ARBs                                  | 14.3      | 17.4       | 21.2      | 14.1      | 16.0       | 13.5      |
| ARB combinations                      | 8.5       | 10.6       | 25.6      | 10.9      | 13.4       | 22.8      |
| Beta-blocking agents                  | 37.1      | 41.2       | 11.1      | 29.4      | 31.3       | 6.5       |
| CCBs                                  | 22.1      | 27.3       | 23.5      | 23.9      | 28.8       | 20.8      |
| Diuretics                             | 28.0      | 32.5       | 16.3      | 15.3      | 20.2       | 32.5      |
| Other antihypertensives               | 6.5       | 6.7        | 3.3       | 5.0       | 6.7        | 34.6      |
| Serum lipid-reducing agents           | 23.9      | 38.8       | 62.7      | 27.1      | 42.0       | 54.9      |
| Aspirin                               | 4.1       | 5.2        | 26.3      | 8.2       | 10.9       | 32.6      |
| Peripheral vasodilators               | 3.0       | 3.5        | 14.3      | 1.5       | 1.5        | 0         |
| Anti-obesity medications              | 0         | 0          | 0         | 0.4       | 0.4        | 0         |
| Others*                               | 2.4       | 4.1        | 72.7      | 2.7       | 4.0        | 50.0      |

*Including antihaemorrhoidal for topical use, corticosteroids and flavonoids. ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; CCB, calcium channel blocker.
domain 4 of the questionnaire, 31.9% of patients said the additional time with their doctor, 14.5% the personal report, 4.0% the follow-up calls and a further 30.9% enjoyed all three equally (16.0% did not answer this question and 2.7% responded ‘none of the above’).

Change in medications from screening to the end of the study
Over the study period, cardiovascular medications were prescribed to 93% of patients in the usual care group and 90% of patients randomised to the intervention. Overall, the use of cardiovascular medications increased from screening to the end of the study in both groups. From screening to month 6, the percentage of patients prescribed cardiovascular medications increased from 82.4% to 93.3% in the usual care group, and from 81.5% to 89.1% in the intervention group (p < 0.0001 for the increase in medication use from screening in both groups; p = 0.059 between groups). The percentage of patients receiving antihypertensives increased from 80.9% to 91.1%, and 77.9% to 84.7%, among usual care and intervention patients respectively, and the use of serum lipid-reducing agents from 23.9% to 38.8%, and 27.1% to 42.0% respectively (Table 3).

Adverse events
A total of 34 patients, including two usual care patients who died (causes of death were cardiac arrest and sudden death), experienced 38 serious AEs (SAEs). The most common SAEs were cardiac disorders, including MI (three patients), cardiac arrest (one patient), coronary artery disease (one patient), myocardial ischaemia (one patient) and tachycardia (one patient). AEs reported by ≥ 1% of patients in the usual care or intervention group are listed in Table 4. The percentage of patients who discontinued from the study was 2.8% in the usual care group and 1.9% in the intervention group. The most common reason for discontinuation in both groups was that the patient defaulted (2.0% and 1.4% in the usual care and intervention groups respectively) (Figure 2).

Discussion
The REACH OUT study demonstrated that a CHD risk evaluation and communication programme mediates a statistically significant reduction in predicted Framingham cardiovascular risk when compared with usual care, among patients with hypertension and moderate cardiovascular risk. At the end of the 6-month study period, patients receiving the intervention had an approximately 10% lower relative predicted 10-year risk of CHD compared with patients given usual care only. Furthermore, patients in the intervention group were observed to have a significantly lower modifiable risk (which excludes the effects of age and gender on predicted CHD risk), relative to those receiving usual care.

Improvements in risk factor management with intervention vs. usual care
At 6 months, statistically significant differences were observed between the intervention and usual care groups for blood pressure decreases and smoking cessation. Indeed, approximately 8% more patients in the intervention group were reported to have quit smoking during the study than in the usual care group. Reductions in total cholesterol were also numerically greater with the intervention than with usual care, although differences between groups did not reach statistical significance. Framingham risk reductions driven by changes in these factors were impressive in both groups [18% relative reduction with usual care (adjusted absolute reduction 4.9 percentage points); 26% with intervention (adjusted absolute reduction 6.3 percentage points)], particularly given that the majority of patients were already receiving cardiovascular medications at screening. Additionally, improvements in factors such as LDL-C and weight loss, while not reflected in the Framingham risk estimates, nonetheless contribute to a positive change in patients’ overall risk profiles. Importantly, approximately twice as many patients in the intervention group achieved blood pressure and LDL-C goals compared with usual care, implying an improvement in the treatment of these risk factors towards guideline-recommended targets by physicians.

While it is not possible to determine precisely the causes of improved CHD risk reduction mediated by

Table 4 Adverse events reported by ≥ 1% of patients in the usual care or intervention group

| Adverse event                  | Usual care (N = 538) | Intervention (N = 565) |
|-------------------------------|----------------------|------------------------|
| Back pain                     | 21 (3.9)             | 16 (2.8)               |
| Headache                      | 10 (1.9)             | 12 (2.1)               |
| Cough                         | 6 (1.1)              | 10 (1.8)               |
| Upper respiratory tract infection | 3 (0.6)           | 8 (1.4)                |
| Osteoarthritis                | 6 (1.1)              | 8 (1.4)                |
| Pharyngitis                   | 12 (2.2)             | 7 (1.2)                |
| Abdominal pain                | 2 (0.4)              | 6 (1.1)                |
| Bronchitis                    | 18 (3.3)             | 6 (1.1)                |
| Dyslipidaemia                 | 8 (1.5)              | 6 (1.1)                |
the REACH OUT intervention, the observed benefits are likely attributable to behaviour modifications among both physicians and patients. The prescription of cardiovascular medications increased in both the intervention and usual care groups over the study period, which likely contributed to observed risk reductions, although overall increases in the use of cardiovascular medications were slightly lower in the intervention group than in the usual care group. Nonetheless, knowledge of patients’ risk status may have prompted physicians to prescribe higher doses of medications or more appropriate therapies. Data for these variables were not collected, however, so firm conclusions cannot be drawn.

Greater interaction with their physician, and increased knowledge and understanding of their risk status, may have motivated patients to adhere to a more healthy diet, increase their exercise, quit smoking or maintain better adherence with medications. The results of the KAB questionnaire demonstrated that patients did indeed experience a small, but statistically significant, increase in their scores for knowledge, attitudes and behaviour, which may have contributed to the observed improvements in CHD risk reduction. Of interest was the finding that patient attitudes appeared to have the greatest correlation with predicted risk, indicating the importance of positively influencing a patient’s attitudes to drug therapy and lifestyle changes. In addition, the Heart Health Report was designed to motivate patients by prompting them to consider their future life goals (e.g. their child’s wedding, retirement, the birth of a grandchild or travelling the world), which may be a further factor in promoting positive lifestyle changes (38). However, only limited data were collected to evaluate these factors, precluding a full assessment of the causal mechanisms.

Despite the benefits of the intervention on patients’ risk factor profiles, the degree of risk reduction in the usual care group was also remarkable. This may be attributed in part to physicians altering their treatment strategies as a result of measuring variables such as blood pressure and lipids during screening procedures, realisation that patients’ risk was ≥10% (required for inclusion), or because of their awareness of the purpose of the study to evaluate the benefits of overall cardiovascular risk assessment. Furthermore, because of their involvement in a clinical trial, and knowledge that their treatment patterns and achieved risk factor reductions were observed as part of the trial protocol, physicians may have dedicated more time to patient consultations than in their usual clinical practice. These hypotheses are supported by observed increases in the prescription of cardiovascular medications, which were slightly greater in the usual care arm than in the intervention arm. Similarly, patients may have experienced an increase in their motivation to adhere to drug therapy and lifestyle changes because of their involvement in a clinical trial. It is therefore possible that the REACH OUT intervention programme may mediate greater incremental benefits in clinical practice, when compared with true ‘usual care’ outside of a clinical trial setting.

**Modifiable risk assessment**

We believe that the assessment of modifiable risk as well as absolute risk is an important clinical concept, which may allow physicians to evaluate more clearly the potential risk reductions that can be achieved with optimal risk factor management. However, it should be noted that estimations of modifiable risk are dependent upon the accepted definition of a ‘normal’ individual. In this study, normal levels of blood pressure and lipids were defined as a systolic blood pressure of 139 mmHg, total cholesterol of 4.9 mmol/l (189 mg/dl) and HDL-C of 1.0 mmol/l (40 mg/dl) for males or 1.2 mmol/l (46 mg/dl) for females (38), which were considered to be levels achievable with the medications readily available in clinical practice. However, clinical outcomes studies have demonstrated benefits of reducing cholesterol to lower levels, particularly among high-risk patients or those with prior CHD (42–44), and observations from subanalyses and epidemiological studies suggest that reducing blood pressure to lower levels may have similar benefits (45–50). In addition, the normal individual for the purposes of this study was defined as not receiving antihypertensive treatment. Thus, in the calculation of modifiable risk, a previously untreated patient would have an increase in their modifiable risk if given antihypertensive therapy during the study, unless this was offset by a considerable reduction in systolic blood pressure. The changes in modifiable risk reported in this study are therefore conservative.

**Implications for clinical practice**

Several studies have demonstrated that patient education and support strategies can help to improve patient adherence to medications and mediate improvements in risk factor modification in clinical practice (27–37). These include large trials of nurse-led interventions such as the recent EuroAction trial and the Oxford and collaborators health check (OXCHECK) studies. In EuroAction (27–29), patients with high cardiovascular risk receiving a 16-week, nurse-led cardiovascular prevention and rehabilitation programme experienced significant benefits in terms of risk factor reductions and dietary improve-
ments at one year of follow-up. Overall, there was a comparable absolute difference in blood pressure and LDL-C goal attainment between EuroAction and REACH OUT among high-risk patients receiving the intervention vs. usual care (58% vs. 41%, respectively, for blood pressure; 45% vs. 35%, respectively, for LDL-C). In contrast to REACH OUT, more patients received statins (38% vs. 23%, p = 0.03) and angiotensin-converting enzyme inhibitors (29% vs. 20%, p = 0.02) in the intervention group than in the usual care group, which likely contributed to the benefits observed in EuroAction. In addition, a similar nurse-led, family-oriented cardiovascular screening and lifestyle intervention programme in the earlier British Family Heart Study was associated with a 12% reduction in predicted coronary risk (51). In OXCHECK nurses provided regular patient health checks, which were associated with significantly lower levels of blood pressure (−2.5/1.5 mmHg) and total cholesterol [−0.19 mmol/l (7.3 mg/dl)] vs. the control group at 3 years’ follow-up (30). The authors for the OXCHECK study suggest that these observed reductions in blood pressure would translate to a long-term reduction in risk of MI of 7%, and the decreases in cholesterol to a risk reduction of 6% in men and 13% in women (30).

However, previous studies specifically evaluating the benefits of cardiovascular risk assessment and communication have demonstrated little or no effect on predicted CHD risk (24–26). In the recent Cardiovascular Health Evaluation to improve Compliance and Knowledge among Uninformed Patients (CHECK-UP) study (24), conducted in Canada among patients with previously untreated dyslipidaemia, physicians and patients were informed of the patient’s calculated risk through a one-page printout, and patients received ongoing feedback regarding the change in their risk and reductions in ‘cardiovascular age’ (defined as the patient’s age minus the difference between their estimated remaining life expectancy and the average remaining life expectancy for Canadian individuals of the same age and sex) as a result of lifestyle changes or drug treatment. The CHECK-UP study demonstrated a statistically significant reduction in 10-year Framingham risk of CVD (for patients without CVD) with the intervention vs. usual care; however, the between-group difference was only approximately −0.6 percentage points (−5.9 with intervention vs. −5.3 with usual care), or about half as effective as the REACH OUT intervention (−1.4 percentage points). Although the REACH OUT study design and patient population are not directly comparable with these earlier studies (24–26), the favourable results observed with the risk evaluation and communication programme may be an indication of the effectiveness of the Heart Health Report for communicating CHD risk, and/or the benefits of the additional follow-up calls from the physician or study nurse.

Elements of the intervention in REACH OUT that focus on increased communication between providers and patients could potentially be provided not only by physicians but also by nursing staff, pharmacists or other healthcare workers, and incorporated relatively easily into routine clinical practice. However, in order to achieve greater improvements in modifiable risk factors than those achieved by patient education/counselling alone (30,34,36,52), it may be beneficial to consider additional interventions as part of a multifactorial approach, for example, adherence interventions (32,35), or CHD risk evaluation as in REACH OUT. In contrast to large-scale interventions such as that in the EuroAction study (27–29) that, if implemented in clinical practice, would require the hiring of additional nursing staff and the associated costs, the REACH OUT intervention could potentially be provided by existing healthcare workers, with only the costs related to the small increase in time devoted to each patient. However, a direct comparison of various investments of clinician’s time would be required to fully understand the value of the REACH OUT intervention compared with alternatives. We have no measurement of the exact time that the physician or nurse spent with the patient in REACH OUT (although 78% of patients reported that the physician spent more than 5 min explaining the report), which would be an important factor in determining the cost-effectiveness of the intervention.

Despite the reductions in risk achieved, at the end of the study patients’ modifiable risk in both the intervention and usual care groups remained approximately twice as high as for an individual with normal blood pressure and lipids, indicating that additional benefit could be gained from further reductions in modifiable risk factors. Notably, overall levels of blood pressure and LDL-C goal attainment observed in REACH OUT were good when compared with those in usual clinical practice (9,10), but were lower than those achieved in recent clinical trials of antihypertensive and lipid-lowering therapies among patients at varying levels of cardiovascular risk (53–55). In particular, reductions in lipid levels were smaller in REACH OUT than in these other trials, contributing to markedly lower levels of LDL-C goal attainment (53–55). Similarly, the achieved reductions in Framingham risk were smaller than those demonstrated in recent studies evaluating concomitant blood pressure and lipid-lowering therapy (54,56). This may be due to above-average levels of
adherence to allocated study medications in these trials, but also suggests that the treatment strategies employed by physicians in REACH OUT and in clinical practice could be improved, perhaps with the use of newer treatments, greater titration of medications or the addition of statin therapy in patients with hypertension and additional risk factors (6). Interventions with the potential to improve patient adherence, for instance the use of single-pill combination therapies or blister packs to improve convenience of dosing (32,35,57,58), could provide further benefits to improve risk factor control (59–62).

Limitations and additional considerations
Concerns were raised by the Ethics Committee in Norway that informing patients of their cardiovascular risk may generate unnecessary anxiety, and the Norwegian committee did not approve the REACH OUT protocol on these grounds. In addition, during the screening process, a number of patients were excluded as they did not wish to be informed of their cardiovascular risk. However, we believe that the REACH OUT study helps to confirm that a realistic perception of cardiovascular risk can motivate patients and physicians to improve risk factor control when combined with a follow-up and support strategy. This concept is supported by a study by Troein et al. (63), which indicated that providing supportive information on cardiovascular risk factors does not increase patient anxiety. Nonetheless, this issue is worthy of consideration and risk communication should be addressed sensitively.

The Framingham calculation was chosen as the method of risk estimation used in REACH OUT as this model is a well understood and effective tool to summarise multiple risk factors and global cardiovascular risk (21,41). It is a limitation of this study, however, that the Framingham model has not been validated broadly in European populations and has been reported to overestimate absolute CHD risk in some studies of European patients (64,65). Furthermore, risk algorithms are not validated for the assessment of treatment effects. Short-term reductions in risk factors leading to reduced estimates of Framingham risk will not necessarily eliminate associated accumulated risks; patients need to maintain these improvements over the long term to reduce their actual risk of disease, and it is uncertain whether the accumulated effects of long-term elevations in risk factors are entirely reversible even with prolonged therapeutic control. In addition, daily biological variations in blood pressure and lipid measurements can affect the precision of risk estimations (66). Risk algorithms can only provide an estimation of long-term risk, and no one method for risk prediction is perfect (67). However, as these limiting factors will be equal in both treatment arms, the between-group differences are still meaningful and we believe that relative changes in predicted risk following intervention can provide a useful indication of the potential benefits if improvements are maintained. In order to accurately determine the true effect of our intervention on cardiovascular outcomes, long-term follow-up studies of patient cardiovascular events are required.

Few women met the REACH OUT study inclusion criterion of 10-year absolute risk $\geq 10\%$, and those who were included had a high modifiable risk compared with the male population. Thus, the findings from REACH OUT may need to be verified among a greater sample of female patients. Similarly, our findings do not necessarily extend to patients with a history of CHD or diabetes, patients with predicted risk scores $< 10\%$ or those who are $\geq 65$ years of age, as all of these groups were excluded from the study. An additional study limitation is the relatively short follow-up period of 6 months, which precludes inferences about the long-term impact of the intervention on sustaining improvements in modifiable risk factors and cardiovascular risk reduction.

Conclusions
The REACH OUT study demonstrates that a patient-focused, physician-implemented CHD risk evaluation and communication programme can effectively lower predicted CHD risk compared with usual care among patients with hypertension and elevated cardiovascular risk, through improvements in modifiable risk factors. This strategy for achieving benefits in risk reduction without dictating drug therapy has wide applicability and is of public health importance. These data support the role of global CHD risk assessment, risk communication and risk factor education for CHD prevention in a multinational, primary care setting. By combining this risk evaluation and communication strategy with more intensive treatment to reduce residual modifiable cardiovascular risk, we believe that substantial improvements in CVD prevention could be achieved in clinical practice.

Acknowledgements
This study was sponsored by Pfizer Inc, who were involved in the study design, data collection, data analysis, manuscript preparation and publication decisions. Editorial support was provided by Dr Elizabeth Harvey of Envision Pharma, and funded by Pfizer Inc. Joshua Benner and Spencer Cherry were employees of IMS Health, Inc., who were paid
consultants to Pfizer Inc in connection with this study and the development of the manuscript. The authors would like to thank all investigators and Pfizer staff for their support.

Author contributions

All authors were members of the REACH OUT Steering Committee and as such were involved in the design and development of the trial protocol, and in the interpretation of the data. N. Rajicic was primarily responsible for the statistical analysis of the data. All authors contributed to the critical revision of the article and approval of the final manuscript.

References

1 Rosamond W, Flegal K, Furie K et al. Heart disease and stroke statistics – 2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2008; 117: e25–146.

2 Greenland P, Knoll MD, Stamler J et al. Major risk factors as antecedents of fatal and nonfatal coronary heart disease events. JAMA 2003; 290: 891–7.

3 Neaton JD, Wentworth D. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316,099 white men. Multiple Risk Factor Intervention Trial Research Group. Arch Intern Med 1992; 152: 56–64.

4 Baigent C, Keech A, Kearney PM et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267–78.

5 Turnbull F, Neal B, Algert C et al. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overview of randomized trials. Arch Intern Med 2005; 165: 1410–9.

6 Sever PS, Dahlo¨ f B, Poulter NR et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361: 1149–58.

7 Goede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008; 358: 580–91.

8 Cheung BM, Launder IJ, Lau CP, Kumana CR. Meta-analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes. Br J Clin Pharmacol 2004; 57: 640–51.

9 Johnson ML, Pietz K, Battlement DS, Bhyth RJ. Therapeutic goal attainment in patients with hypertension and dyslipidemia. Med Care 2006; 44: 39–46.

10 Wong ND, Lopez V, Tang S, Williams GR. Prevalence, treatment, and control of combined hypertension and hypercholesterolemia in the United States. Am J Cardiol 2006; 98: 204–8.

11 Roccatagliata D, Avanzini F, Monesi L et al. Is global cardiovascular risk considered in current practice? Treatment and control of hypertension, hyperlipidemia, and diabetes according to patients’ risk level. Vasc Health Risk Manag 2006; 2: 507–14.

12 Wolf-Maier K, Cooper RS, Kramer H et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension 2004; 43: 10–7.

13 Wright DJ, Grayson AD, Jackson M, Dainty C. The reality of treating dyslipidaemia in patients with coronary heart disease: a primary care survey. Int J Clin Pract 2005; 59: 488–91.

14 Wood DA. Clinical reality of coronary prevention in Europe: a comparison of EUROASPIRE I, II and III surveys. Presented at the European Society of Cardiology Congress, Vienna, Austria, September 1–5, 2007.

15 Chapman RH, Benner JS, Petrilla AA et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med 2005; 165: 1147–52.

16 Hobbs FD, Erhardt L. Acceptance of guideline recommendations and perceived implementation of coronary heart disease prevention among primary care physicians in five European countries: the Reassessing European Attitudes about Cardiovascular Treatment (REACT) survey. Fam Pract 2002; 19: 596–604.

17 Erhardt LR, Hobbs FD. A global survey of physicians’ perceptions on cholesterol management: the From The Heart study. Int J Clin Pract 2007; 61: 1076–85.

18 Erhardt L, Moller R, Puig JG. Comprehensive cardiovascular risk management – what does it mean in practice? Vasc Health Risk Manag 2007; 3: 587–603.

19 Graham I, Attar D, Borch-Johnsen K et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur Heart J 2007; 28: 2375–414.

20 Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486–97.

21 Wilson PW, D’Agostino RB, Levy D et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97: 1837–47.

22 Assmann G, Callen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the Prospective Cardiovascular Munster (PROCAM) study. Circulation 2002; 105: 310–5.

23 Conroy RM, Pyorala K, Fitzgerald AP et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003; 24: 987–1003.

24 Grover SA, Lowenstein I, Joseph I et al. Patient knowledge of coronary risk profile improves the effectiveness of dyslipidemia therapy: the CHECK-UP study: a randomized controlled trial. Arch Intern Med 2007; 167: 2296–303.

25 Lowenstein I, Joseph I, Levinson C et al. Can computerized risk profiles help patients improve their coronary risk? The results of the Coronary Health Assessment Study (CHAS). Prev Med 1998; 1: 730–7.

26 Montgomery AA, Fahey T, Peters TJ et al. Evaluation of computer based clinical decision support system and risk chart for management of hypertension in primary care: randomised controlled trial. BMJ 2000; 320: 686–90.

27 Wood DA, on behalf of the EUROACTION group. EUROAC- TION: a nurse lead multidisciplinary preventive cardiology programme for coronary patients, high risk individuals and their families. Eur Heart J 2006; 27: 2896–9.

28 Wood DA, Kotseva K, Jennings C et al. EUROACTION: a European Society of Cardiology demonstration project in preventive cardiology. A cluster randomised controlled trial of a multi-disciplinary preventive cardiology programme for coronary patients, asymptomatic high risk individuals and their families. Summary of design, methodology, and outcomes. Eur Heart J Suppl 2004; 6 (Suppl. J): 13–15.

29 Wood DA, Kotseva K, Connolly S et al. Nurse-coordinated multidisciplinary, family-based cardiovascular disease prevention programme (EUROACTION) for patients with coronary heart disease and asymptomatic individuals at high risk of cardiovascular...
45 Nissen SE, Tuzcu EM, Libby P et al. Effect of antihypertensive
medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol: a randomized controlled trial. 

46 Sipahi I, Tuzcu EM, Schoenhagen P et al. Effects of normal, pre-hypertensive, and hypertensive blood pressure levels on progression of coronary atherosclerosis. J Am Coll Cardiol 2006; 48: 833–8.

47 Adler AI, Stratton IM, Neil HA et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000; 321: 412–9.

48 Flack JM, Neaton J, Grimm R Jr et al. Blood pressure and mortality among men with prior myocardial infarction. Multiple Risk Factor Intervention Trial Research Group. Circulation 1995; 92: 2437–45.

49 MacMahon S, Petro R, Cutler J et al. Blood pressure, stroke, and coronary heart disease. Part 1. Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335: 765–74.

50 Kostis JB, Brazzina A, Deedwania PC, LaRosa JC. The benefits of intensive lipid lowering in patients with stable coronary heart disease with normal or high systolic blood pressure: an analysis of the Treating to New Targets (TNT) study. J Clin Hypertens 2008; 10: 367–76.

51 Wood DA, Kimmoth AL, Davies GA et al. Randomised controlled trial evaluating cardiovascular screening and intervention in general practice: principal results of British family heart study. Family Heart Study Group. BMJ 1994; 308: 313–20.

52 Friedman RH, Kazis LE, Jette A et al. A telecommunications system for monitoring and counseling patients with hypertension. Impact on medication adherence and blood pressure control. Am J Hypertens 1996; 9: 285–92.

53 Blank R, LaSalle J, Reeves R et al. Single-pill therapy in the treatment of concomitant hypertension and dyslipidemia (the Amlodipine/Atorvastatin Gemini Study). J Clin Hypertens 2005; 7: 264–73.

54 Messerli FH, Bakris GL, Ferrara D et al. Efficacy and safety of coadministered amlodipine and atorvastatin in patients with hypertension and dyslipidemia: results of the AVALON trial. J Clin Hypertens (Greenwich) 2006; 8: 571–81.

55 Flack JM, Victor R, Watson K et al. Improved attainment of blood pressure and cholesterol goals using single-pill amlodipine/atorvastatin in African Americans: the CAPABLE trial. Mayo Clin Proc 2008; 83: 35–45.

56 Preston RA, Harvey P, Herrfert O et al. A randomized, placebo-controlled trial to evaluate the efficacy, safety, and pharmacodynamic interaction of coadministered amlodipine and atorvastatin in 1660 patients with concomitant hypertension and dyslipidemia: the respond trial. J Clin Pharmacol 2007; 47: 1555–69.

57 Bangalore S, Shahane A, Parkar S, Messerli FH. Compliance and fixed-dose combination therapy. Curr Hypertens Rep 2007; 9: 184–9.

58 Patel BV, Leslie RS, Thiebaud P et al. Adherence with single-pill amlodipine/atorvastatin vs a two-pill regimen. Vasc Health Risk Manag 2008; 4 [online ahead of print].

59 Bramley TJ, Gerbino PP, Nightengale BS, Frech-Tamas F. Relationship of blood pressure control to adherence with antihypertensive monotherapy in 13 managed care organizations. J Manag Care Pharm 2006; 12: 239–45.

60 Wei L, Wang J, Thompson P et al. Adherence to statin treatment and readmission of patients after myocardial infarction: a six-year follow up study. Heart 2002; 88: 229–33.

61 Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care 2005; 43: 521–30.

62 Ho PM, Rumfield JS, Masoudi FA et al. Effect of medication non-adherence on hospitalization and mortality among patients with diabetes mellitus. Arch Intern Med 2006; 166: 1836–41.

63 Troen M, Råstam L, Selander S. Changes in health beliefs after labelling with hypercholesterolemia. Scand J Public Health 2002; 30: 76–9.

64 Eichler K, Puhlan MA, Steurer J, Bachmann LM. Prediction of first coronary events with the Framingham score: a systematic review. Am J Heart 2007; 153: 722–31.

65 Empiana JP, Ducimetiere P, Arveiler D et al. Are the Framingham and PROCAM coronary heart disease risk functions applicable to different European populations? The PRIME Study. Eur Heart J 2003; 24: 1903–11.

66 Reynolds TM, Twomey P, Wierzbicki AS. Accuracy of cardiovascular risk estimation for primary prevention in patients without diabetes. J Cardiovasc Risk 2002; 9: 183–90.
67 Giavarina D, Barzon E, Cigolini M et al. Comparison of methods to identify individuals at increased risk of cardiovascular disease in Italian cohorts. *Nutr Metab Cardiovasc Dis* 2007; 17: 311–8.

*Paper received February 2008, accepted June 2008*

**Appendix**

The REACH OUT study investigators (listed by country).

**Czech Republic:** Dr Tomas Dacik, Dr Marta Fialova, Dr Vaclav Hanka, Dr Radvana Komperova, Dr Marcela Malcova, Dr Vladimir Marek, Dr Jarmila Pavlovcicova, Dr Anna Seborova, Dr Anna Uglajova, Dr Milena Hofmanova, Dr Miloslav Fiser, Dr Zdenek Vlasak, Dr Hana Sediva and Dr Helena Hajkova.

**Denmark:** Dr Kim Brockelmann, Dr Niels J. Winther-Pedersen, Dr Preben Kjaerhus, Dr Jesper Isaksen, Dr Jens V. Faaborg-Andersen, Dr Carsten Kjellerup, Dr Mogens Bang, Dr Soren Faurschou and Dr Torben Muller.

**France:** Dr Jacques Marty, Dr Michel Arnaud, Dr Leon Grynsztejn, Dr Jean-marie Letzelter, Dr Bernard Perrin, Dr Francois Polard, Dr Pierre Sebastien, Khaled Mekki, Jean Louis Navarre, Dr Claude Burguier, Dr Michel Chay and Dr Christophe Robert.

**Germany:** Dr Lutz Gabriel, Dr Burkhard Wieckinger, Dr Ursula Schax, Dr Gerard Tangerding, Dr Bastian Steinberg, Dr Hans Germann, Dr Christiane Klein, Dr Hannelore Pitule, Dr Volker Aldinger, Dr Klaus Werner, Dr Ottmar Herfert and Dr Thomas Schaefr.

**Greece:** Dr Styliani Argyriadou, Associate Professor Christos Lionis, Dr Antonios Batikas, Dr Marios Chatziarsenis, Dr Athanasios Symeonidis and Dr Dimitris Karanasios.

**The Netherlands:** F. A. A. M. Vermetten, Dr Peter D. M. Coenen, Ivo G. C. M. Bierens, Cees P. Buiks, Aart Leemhuis, W. C. J. van Broekhoven, C. P. Schapers-de Bruin, F. R. de Jong, A. J. M. Boermans, Harry F. C. M. van Mierlo, Willem Veerman and Wilfried A. De Backer.

**Poland:** Dr Renata Piotrowska, Dr Ireneusz Szymbczyk, Dr Andrzej Zajac, Dr Piotr Pietrzak, Dr Adam Ptasinski, Dr Dariusz Horszczaruk, Dr Maria Sledzinska, Dr Irena Gasiorowska, Dr Jacek Kalamarz, Dr Joanna Bocian-Sobkowska, Dr Danuta Widerska-Sobczak, Dr Krzysztof Kliks, Dr Magdalena Kaczmarek and Dr Danuta Kwiatkowska.

**Spain:** Armando Nevado Loro, Jose Luis Martinez Carrasco, Juan Jose Gonzalez Marco, Isabel Saenz del Castillo, Jose Luis Anton Castello, Antonio Rivera Castellano, Amadeo Belles, Juan Jose Martinez Lahurta, Rafael Alario and Jose Baleriola.

**Sweden:** Dr Goran Hedberg, Dr Sylvia Wide, Dr Roberto M. Zucchini, Dr Margareta Wargelius, Dr Eva Angesjo, Dr Gustav Melin, Bo Sundqvist, Dr Lars Henningsson, Dr Lars Sarhammar, Dr Ann Charlotte Weiderman and Tomas Rahm.

**Supporting information**

Additional supporting information may be found in the online version of this article.

**Figure S1 Heart Health Report**

Please note: Wiley-Blackwell are not responsible for the content or functionality of any supporting materials supplied by the authors. Any queries (other than missing material) should be directed to the corresponding author for the article.